Aroa Biosurgery Ltd
ASX:ARX

Watchlist Manager
Aroa Biosurgery Ltd Logo
Aroa Biosurgery Ltd
ASX:ARX
Watchlist
Price: 0.655 AUD -2.24% Market Closed
Market Cap: 226m AUD

EV/EBIT
Enterprise Value to EBIT

382.3
Current
-34.2
Median
7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
382.3
=
Enterprise Value
210.4m AUD
/
EBIT
630k NZD
All Countries
Close
EBIT Growth EV/EBIT to Growth
NZ
Aroa Biosurgery Ltd
ASX:ARX
Average EV/EBIT: 82.5
382.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.1
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
121.9
2-Years Forward
EV/EBIT
22.4
3-Years Forward
EV/EBIT
13.8